Navigation Links
SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
Date:11/30/2007

FREDERICK, Md, Nov. 30 /PRNewswire/ -- SuperArray Bioscience Corporation announced today that it has entered into a RNA Interference (RNAi) license agreement with The Carnegie Institution. Under the agreement, SuperArray Bioscience Corporation will develop, manufacture and distribute worldwide RNA interference based gene function and mechanism of action research tools.

The agreement enables SuperArray to offer RNAi-based gene silencing products for gene function studies including gene-specific small interfering RNA (siRNA) and DNA-based RNA interference expressing short hairpin RNA (shRNA). The agreement also allows SuperArray to pass on rights to end-user customers in the research field for the performance of DNA-based RNA Interference.

RNA Interference is a key technology in life science research, particularly in gene function studies and in drug target identification. A small piece of RNA with complete sequence identity to a target gene of interest is introduced or "transfected" into an in vitro mammalian cell culture system. A normal cellular process uses the small RNA to identify and degrade the messenger RNA responsible for the expression of the same targeted gene. Suppressing the expression of the gene removes the activity of its protein product. The researcher then performs other biological experiments with the cells to determine the missing or changed activity and to attribute that activity to the gene of interest.

"We are very excited to offer RNA Interference-based gene function research tools using the technologies from The Carnegie Institution," said Dr. Paul Nisson, Senior Director of Technology Development at SuperArray Bioscience Inc. "Our combination of a multi-purpose plasmid backbone and a rigorously experimentally verified design algorithm to produce gene-specific RNA Interference for every gene in human, rat and mouse genome will help biomedical researchers identify the function of novel genes or further explore the role of important genes. We also plan to use SuperArray's unique capability to examine pathways in an integrated approach to greatly expand the application of RNA Interference in drug discovery and biomedical research."

The patent has been licensed to SuperArray Bioscience Corporation on a non-exclusive basis.

About SuperArray Bioscience Corporation

SuperArray Bioscience Corporation, a privately held biotechnology company founded in 1998, envisions a new and systematic approach to biological research in the post-genomic era. We have developed a broad portfolio of innovative and cost-effective research tools based on current knowledge and understanding of important biological pathways that merge the benefits of hypothesis-driven and discovery-based research. Our goal is to provide practical research tools that accelerate, simplify and improve life science research.

http://www.superarray.com


'/>"/>
SOURCE SuperArray Bioscience Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: